Read more stories about
Montana Business >>

MATR Sponsor:

MATR Supporters:

Bozeman, Montana's LigoCyte Sold to Takeda Pharmaceutical

October 5, 2012View for printing

Takeda Pharmaceutical is to buy biopharma LigoCyte for $60 million in cash, plus future milestone-dependent payments. LigoCyte is developing a pipeline of virus-like particle (VLP)-based vaccines for gastrointestinal and respiratory infections. The firm's pipeline is headed by a norovirus vaccine candidate that is in Phase I/II clinical development, and preclinical-stage candidates against respiratory syncytial virus (RSV), pandemic and seasonal influenza, and rotavirus.

For the foreseeable future the firm plans to continue operating LigoCyte at the latter's site in Bozeman, Montana, and retain its management team and employees.

Full Story: ... e/81247440/
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!